ArticleGynecologic oncology reports2025
Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fueling the Seed: Growth Factors and Cytokines Driving Cancer Stem Cells in Gynecological Malignancies.International journal of molecular sciences · 2025Review
- The molecular classification ushers in a new era for the treatment of advanced and recurrent endometrial cancer.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe a case of sustained disease control for over five years in a patient with recurrent, advanced endometrial cancer treated with lenvatinib and pembrolizumab, despite significant treatment-related toxicities. Methods: We present a 49-year-old patient with grade 3, stage IVB endometrioid endometrial adenocarcinoma. After cytoreductive surgery, carboplatin and paclitaxel chemotherapy, and radiation therapy, the patient experienced progression with widespread metastases. She was then treated with lenvatinib (20 mg daily) and pembrolizumab (200 mg every three weeks). The patient experienced multiple treatment-related adverse events, including hypertension, colitis, hypothyroidism, adrenal insufficiency, and ocular toxicity, requiring dose adjustments and treatment interruptions. Results: Despite frequent toxicities, the patient achieved a durable response to lenvatinib and pembrolizumab. Five years after treatment initiation, imaging showed no metabolically active disease, with only minimal stable residual lesions. Careful management of adverse effects, including supportive care, dose modifications, and temporary treatment pauses, enabled continued therapy. Conclusion: This case underscores the potential for long-term disease control with lenvatinib and pembrolizumab in advanced endometrial cancer, even in patients with proficient mismatch repair (pMMR) and low tumor mutational burden. Although toxicities can require treatment adjustments, they can often be effectively managed, allowing for prolonged therapy. Further research is needed to determine the optimal treatment duration and strategies to mitigate long-term side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.